Haydar Frangoul, MD

Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial, discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.

The medical director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the pros and cons of potentially curative treatment options for SCD.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed unmet needs that remain after gene therapy approval for SCD.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed his experience with and reaction to the approval of Casgevy.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.